Futura Medical plc is a pharmaceutical group that develops innovative products for the consumer healthcare market.
The Company's shares trade on the AIM market of the London Stock Exchange.
Futura Medical is committed to developing products with the potential for a significant return on the costs of development.
We have five products in our development pipeline for sexual healthcare and pain relief management: CSD500, PET500, MED2002, TPR100 and RAD100. We are evaluating further product opportunities for our proprietary delivery system DermaSys® with a range of other compounds.
SSL International plc ("SSL") has global distribution rights for our condom product CSD500 which will be our first product to market. We also have with SSL a global development and licensing agreement for MED2002, our erectile dysfunction gel. In addition, we are in non-exclusive discussions for the distribution rights to our products for topical pain relief TPR100 and for premature ejaculation PET500.
